T 705

  • Check with publisher
  • Published date: August 4, 2020
    • Shirley, New York, United States

Favipiravir, also known as T-705 or Avigan, is an experimental antiviral drug being developed by Toyama Chemical of Japan with activity against many RNA viruses. Like some other experimental antiviral drugs (T-1105 and T-1106), it is a pyrazinecarboxamide derivative. Favipiravir is active against influenza viruses, West Nile virus, yellow fever virus, foot-and-mouth disease virus as well as other flaviviruses, arenaviruses, bunyaviruses and alphaviruses. Activity against enteroviruses and Rift Valley fever virus has also been demonstrated.https://www.bocsci.com/t-705-cas-259793-96-9-item-84-463609.html

Result 0 votes
Alex Brown
0 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Carmustine

    Carmustine

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    Carmustine is antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. This agent also carbamoylates proteins, including DNA r...

  • Arbidol

    Arbidol

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    Arbidol is an antiviral agent using for the treatment of influenza infection in Russia and China. It inhibits membrane fusion and prevents contact between the virus and target host cells. Fusion between the viral capsid and the cell membrane of the t...

  • Letermovir

    Letermovir

    Drug Development Shirley (New York) August 4, 2020 Check with publisher

    Letermovir is a novel anti-CMV compound which targets the pUL56 (amino acid 230-370) subunit of the viral terminase complex and remains active against virus resistant to DNA polymerase inhibitors. It has a novel mode of action targets the enzyme UL56...